← feed

Is NCT00532675 results overdue?

Yes — results are overdue. Primary completion was 2017-11-08; the FDAAA-801 reporting deadline (2018-11-08) passed 2782 days ago and no results are posted on ClinicalTrials.gov.

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

NCT IDNCT00532675 ↗
SponsorNovartis Pharmaceuticals (INDUSTRY)
Public issuerNOVARTIS AG — NVS (CIK 0001114448) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2017-11-08 (ACTUAL)
Reporting deadline2018-11-08 (completion + 365d)
Days overdue2782
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 8d7c32598e925772… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT00532675. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →